Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by JPPOUGET
Group name EquipeJPP
Item Type Journal Article
Title AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications
Creator Fersing et al.
Author Cyril Fersing
Author Nicolas Masurier
Author Léa Rubira
Author Emmanuel Deshayes
Author Vincent Lisowski
Abstract With the development of 68Ga and 177Lu radiochemistry, theranostic approaches in modern nuclear medicine enabling patient-centered personalized medicine applications have been growing in the last decade. In conjunction with the search for new relevant molecular targets, the design of innovative chelating agents to easily form stable complexes with various radiometals for theranostic applications has gained evident momentum. Initially conceived for magnetic resonance imaging applications, the chelating agent AAZTA features a mesocyclic seven-membered diazepane ring, conferring some of the properties of both acyclic and macrocyclic chelating agents. Described in the early 2000s, AAZTA and its derivatives exhibited interesting properties once complexed with metals and radiometals, combining a fast kinetic of formation with a slow kinetic of dissociation. Importantly, the extremely short coordination reaction times allowed by AAZTA derivatives were particularly suitable for short half-life radioelements (i.e., 68Ga). In view of these particular characteristics, the scope of this review is to provide a survey on the design, synthesis, and applications in the nuclear medicine/radiopharmacy field of AAZTA-derived chelators.
Publication Pharmaceuticals (Basel, Switzerland)
Volume 15
Issue 2
Pages 234
Date 2022-02-16
Journal Abbr Pharmaceuticals (Basel)
Language eng
DOI 10.3390/ph15020234
ISSN 1424-8247
Library Catalog PubMed
Extra Number: 2 PMID: 35215346 PMCID: PMC8879111
Tags AAZTA, bifunctional chelator, first-last-coresponding, mesocyclic, nuclear medicine, original, review, Scientific, theranostics
Date Added 2023/11/23 - 12:44:38
Date Modified 2024/12/15 - 12:07:36
Notes and Attachments Full Text (Attachment)
Full Text (Attachment)
Full Text (Attachment)
PubMed entry (Attachment)
PubMed entry (Attachment)
PubMed entry (Attachment)
Texte intégral (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés